NovoCure (NVCR) Non-Current Deferred Tax Liability (2018)

NovoCure (NVCR) posted quarterly Non-Current Deferred Tax Liability of $124000.0 for Q4 2018.

NovoCure (NVCR) Non-Current Deferred Tax Liability (2018) Analysis & Trends

NovoCure (NVCR) has reported Non-Current Deferred Tax Liability for 1 consecutive years, with $124000.0 the latest figure, recorded in Q4 2018.

  • Quarterly Non-Current Deferred Tax Liability changed N/A year-over-year to $124000.0 in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $124000.0 (changed N/A YoY) and the FY2018 annual result came in at $124000.0, changed N/A from the prior year.
  • Non-Current Deferred Tax Liability held at $124000.0 in Q4 2018 per NVCR's latest filing.
  • Over the last five years, Non-Current Deferred Tax Liability for NVCR reached as high as $124000.0 in Q4 2018 and fell as low as $124000.0 in Q4 2018.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 201.40 Bn 194.75 Bn 6.27 Bn
2 Stryker 122.29 Bn 119.41 Bn 3.81 Bn
3 Medtronic 105.01 Bn 96.40 Bn 6.41 Bn
4 Boston Scientific 64.81 Bn 63.59 Bn 3.61 Bn
5 Edwards Lifesciences 55.28 Bn 51.60 Bn 1.29 Bn
6 Dexcom 29.06 Bn 27.94 Bn 750.30 Mn
7 Koninklijke Philips 29.02 Bn 25.93 Bn 2.07 Bn
8 GE HealthCare Technologies 28.27 Bn 26.20 Bn 1.98 Bn
9 Smith & Nephew 25.80 Bn 25.22 Bn -
10 NovoCure 2.28 Bn 1.85 Bn 142.48 Mn

Historic Data

Download Data
DateValue
Dec 31, 2018 124,000.00
Dec 31, 2018 124,000.00